Vertex Pharmaceuticals, Inc.

NASDAQ:VRTX   3:59:57 PM EDT
215.12
+1.96 (+0.92%)
4:00:00 PM EDT: $215.00 -0.12 (-0.06%)
Products

Vertex Announces FDA Approvals Of Trikafta, Symdeko & Kalydeco For Use In People With CF With Certain Rare Mutations

Published: 12/21/2020 19:41 GMT
Vertex Pharmaceuticals, Inc. (VRTX) - Vertex Announces FDA Approvals of Trikafta® (elexacaftor/tezacaftor/ivacaftor and Ivacaftor), Symdeko® (tezacaftor/ivacaftor and Ivacaftor) and Kalydeco® (ivacaftor) for Use in People With Cf With Certain Rare Mutations.
Vertex Pharmaceuticals - Expanded Eligibility for Trikafta to Include People With Cf Ages 12 Years, Older With Certain Mutations in Cftr Gene.
Vertex Pharmaceuticals - Symdeko Also Received Approval to Include Additional Responsive Mutations in People With Cf Ages 6 Yrs & Older.
Vertex Pharmaceuticals - Kalydeco Also Received Approval to Include Additional Responsive Mutations in People With Cf Age 4 Months & Older.